Floatz logo

DYNAMOS

Diabetes Mellitus, Type 2

Beijing Dongfang Biotech Co., Ltd.Small moleculePhase 1Active
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

141 Active assets in the Diabetes Mellitus, Type 2 cohort.

Asset / SponsorPhaseRating
Liraglutide
RenJi Hospital
Phase 4BBB
Semaglutide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Exenatide
Vivani Medical, Inc
Phase 4BBB
Cotadutide
AstraZeneca
Phase 2BBB
Dapagliflozin
Bhavya Bhavya, MD
Phase 4BBB

View all 50 →

Same molecule, other indications

DYNAMOS is also rated in:

malignant pancreatic neoplasmDormant
B
Indicative ·
62 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
B
Indicative ·
60 / 100
View asset →
MASH - Metabolic Dysfunction-Associated SteatohepatitisDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →